EU approves Novartis-Incyte blood cancer drug

September 4, 2012 by Bashir Adigun

Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi.

The drug is approved to reduce swelling of the spleen, one of the symptoms of the disease. The approved the drug in November and it is sold under the name Jakafi. Its generic name is ruxolitinib.

Myelofibrosis causes abnormal blood cells to build up in bone marrow, forming thick that slows the production of healthy blood cells. To make up for the shortage, other organs including the liver and the spleen begin producing blood cells. That causes swelling of the spleen. The condition also causes anemia, fatigue, and pain.

Incyte markets the drug in the U.S. and Novartis, a Swiss drug company, has the rights to market the drug in all other markets as a cancer treatment.

Incyte shares lost 13 cents to $20.16 in afternoon trading and U.S.-traded shares of Novartis slipped 6 cents to $59.32.

Shares of Incyte are down 19 percent since the company reported its second-quarter results on Aug. 2, but in total the stock is up about 60 percent since Jakafi was approved in mid-November.

Explore further: FDA approves first drug for bone marrow disorder

shares

Related Stories

FDA approves first drug for bone marrow disorder

November 16, 2011
The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration

Drug offers relief for symptoms of myelofibrosis

February 29, 2012
People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the ...

EU approves Novartis drug Signifor for Cushing's disease

April 25, 2012
European Union regulators have given Swiss pharmaceutical group Novartis a green light to market its drug Signifor as a treatment for Cushing's disease, the company said Wednesday.

Omontys approved for anemic people with kidney disease

March 27, 2012
(HealthDay) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.